Optimal Strategies for Managing Adverse Events with GPRC5D Bispecifics in Multiple Myeloma : Episode 5
Overview of Other GPRC5D Therapy Clinical Trials
Beth Faiman, CNP, PhD, outlines unique toxicities seen with other GPRC5D-targeted therapies in multiple myeloma.
EP: 1.Long-Term Follow-up Overview: MajesTEC-1 and MagnetisMM-3 Recent Data
EP: 2.Adverse Event Management with BCMA Therapy
EP: 3.GPRC5D Therapy: Unique Challenges in Adverse Event Management
EP: 4.Overview of Long-term Follow-up from MonumenTAL-1
Now Viewing
EP: 5.Overview of Other GPRC5D Therapy Clinical Trials
EP: 6.Administration and Dosing Management
EP: 7.Clinical Perspective on AE Tolerance
EP: 8.Clinical Experience in Managing AEs in GPRC5D Therapy
EP: 9.Management and Supportive Care for CRS and ICANS in GPRC5D Therapy
EP: 10.Insights on REMS Programs and Strategies for Effective Patient Care
EP: 11.Clinical Scenario: AE Management in a Patient with R/R MM on GPRC5D Therapy
EP: 12.Adverse Event Management Strategies in GPRC5D Therapy
EP: 13.Clinical Scenario: AE Management for Bispecific Therapy in R/R MM
Recent Videos
Related Content
